CN104513283B - 吡喃葡萄糖基衍生物及其在医药上的应用 - Google Patents

吡喃葡萄糖基衍生物及其在医药上的应用 Download PDF

Info

Publication number
CN104513283B
CN104513283B CN201410505453.XA CN201410505453A CN104513283B CN 104513283 B CN104513283 B CN 104513283B CN 201410505453 A CN201410505453 A CN 201410505453A CN 104513283 B CN104513283 B CN 104513283B
Authority
CN
China
Prior art keywords
phenyl
methyl
chloro
compound
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410505453.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104513283A (zh
Inventor
魏用刚
温甲平
祝国智
卢泳华
王鹤然
王银彩
原明云
顾峥
伍武勇
康盼盼
张宗远
陈刚
邓炳初
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yichang Hec Changjiang Pharmaceutical Co ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Priority to CN201410505453.XA priority Critical patent/CN104513283B/zh
Publication of CN104513283A publication Critical patent/CN104513283A/zh
Application granted granted Critical
Publication of CN104513283B publication Critical patent/CN104513283B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CN201410505453.XA 2013-09-27 2014-09-26 吡喃葡萄糖基衍生物及其在医药上的应用 Active CN104513283B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410505453.XA CN104513283B (zh) 2013-09-27 2014-09-26 吡喃葡萄糖基衍生物及其在医药上的应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013104504012 2013-09-27
CN201310450401 2013-09-27
CN201410505453.XA CN104513283B (zh) 2013-09-27 2014-09-26 吡喃葡萄糖基衍生物及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN104513283A CN104513283A (zh) 2015-04-15
CN104513283B true CN104513283B (zh) 2018-01-16

Family

ID=52742084

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410505453.XA Active CN104513283B (zh) 2013-09-27 2014-09-26 吡喃葡萄糖基衍生物及其在医药上的应用

Country Status (7)

Country Link
US (1) US9394329B2 (enExample)
EP (1) EP2895490B1 (enExample)
JP (1) JP6450769B2 (enExample)
CN (1) CN104513283B (enExample)
CA (1) CA2889699C (enExample)
ES (1) ES2605886T3 (enExample)
WO (1) WO2015043511A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016173425A1 (en) * 2015-04-30 2016-11-03 Sunshine Lake Pharma Co., Ltd. A glucopyranosyl derivative and preparation method and uses thereof
CN106674294B (zh) * 2015-11-06 2020-07-07 广东东阳光药业有限公司 吡喃葡萄糖基衍生物的结晶形式
ES3005482T3 (en) * 2015-11-27 2025-03-14 Sunshine Lake Pharma Co Ltd A complex of a glucopyranosyl derivative and preparation method and use thereof
CN105646603A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型a及制备方法
CN105646604A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型b及制备方法
JP6965274B2 (ja) * 2016-05-04 2021-11-10 ヨンジーン セラピューティクス カンパニー リミテッドYoungene Therapeutics Co., Ltd. ナトリウム−グルコース結合輸送体阻害剤のアミン溶媒和物、その調製方法およびその適用
CN107778336B (zh) * 2016-08-24 2022-09-27 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物的结晶形式
CN106674245B (zh) * 2017-01-10 2019-07-26 北京中海康医药科技发展有限公司 吡喃葡萄糖基衍生物的制备及医药上的应用
JP2019001746A (ja) * 2017-06-15 2019-01-10 株式会社クラレ ジオールの製造方法
CN107986972A (zh) * 2017-11-10 2018-05-04 潍坊润安化学科技有限公司 一种3-(4-硝基苯氧基)丙酸制备方法
AU2021305132A1 (en) * 2020-07-08 2023-02-09 Sunshine Lake Pharma Co., Ltd. Method for preparing glucopyranosyl derivatives and intermediates thereof
WO2022161377A1 (en) * 2021-01-27 2022-08-04 Sunshine Lake Pharma Co., Ltd. A phamaceutical composition comprising a glucopyranosyl derivative
WO2022204907A1 (en) * 2021-03-30 2022-10-06 Sunshine Lake Pharma Co., Ltd. Method for preparing cocrystal of l-pyroglutamic acid and glucopyranosyl derivative
CN114835563B (zh) * 2022-05-23 2024-04-26 浙江中欣氟材股份有限公司 一种4,4`-二氟二苯甲酮的合成方法
WO2024012568A1 (en) * 2022-07-15 2024-01-18 Sunshine Lake Pharma Co., Ltd. A key intermediate for preparing glucopyranosyl derivatives and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1930141A (zh) * 2004-03-16 2007-03-14 贝林格尔·英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
CN1950389A (zh) * 2004-03-04 2007-04-18 橘生药品工业株式会社 含氮稠环衍生物，含该衍生物的药物组合物，和其作为药物的用途
CN102149717A (zh) * 2008-08-28 2011-08-10 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2,3,4-三醇衍生物
CN102372722A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JP5264183B2 (ja) 2005-02-23 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
WO2006108842A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
WO2007000445A1 (en) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1910390B1 (en) 2005-07-27 2010-05-19 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted ((hetero)cycloalyklethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
JP5175191B2 (ja) 2005-08-30 2013-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
CA2656847A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
CA2664095A1 (en) 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
AR063569A1 (es) 2006-11-06 2009-02-04 Boehringer Ingelheim Int Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion
UA107175C2 (uk) 2007-07-26 2014-12-10 Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
AU2008288770B2 (en) 2007-08-23 2014-06-12 Theracosbio, Llc Benzylbenzene derivatives and methods of use
CL2009000309A1 (es) 2008-02-13 2009-06-26 Sanofi Aventis Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
EA201100503A1 (ru) 2008-09-19 2011-10-31 Новартис Аг Глюкозидные производные и их применения
AU2009294606A1 (en) 2008-09-19 2010-03-25 Novartis Ag Glycoside derivatives and uses thereof
US20100167988A1 (en) 2008-10-22 2010-07-01 Auspex Pharmaceuticals, Inc. Ethoxyphenylmethyl inhibitors of sglt2
DK2486029T3 (en) 2009-09-30 2015-08-24 Boehringer Ingelheim Int Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
KR20120087950A (ko) 2009-10-20 2012-08-07 노파르티스 아게 글리코시드 유도체 및 그의 용도
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
CN102134226B (zh) 2010-01-26 2013-06-12 天津药物研究院 一类苯基c-葡萄糖苷衍生物、其制备方法和用途
WO2012003811A1 (en) 2010-07-09 2012-01-12 Zhejiang Beta Pharma Inc. C-aryl glucoside sglt2 inhibitors and method
JP2013224263A (ja) 2010-08-19 2013-10-31 Taisho Pharmaceutical Co Ltd ４−イソプロピルフェニルグルシトール化合物
US9161945B2 (en) 2010-08-20 2015-10-20 Taisho Pharmaceutical Co., Ltd. 4-isopropyl-6-methoxyphenyl glucitol compound
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
JP6105489B2 (ja) 2011-02-18 2017-03-29 シャンハイ インリ ファーマシューティカル カンパニー リミティド アリールグルコシド化合物、その調製方法及び使用
CN102675378A (zh) 2011-03-09 2012-09-19 天津药物研究院 一类含环丙烷结构的c-葡萄糖苷衍生物、其制备方法和用途
JP2014510782A (ja) 2011-04-14 2014-05-01 ノバルティス アーゲー グリコシド誘導体およびその使用
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
EP2703396B1 (en) 2011-04-25 2016-06-22 Beijing Prelude Pharm. Sci.& Tech. Co., Ltd. Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
US20140228303A1 (en) 2011-06-13 2014-08-14 Panacea Biotec Ltd Novel sglt inhibitors
EP2725031B1 (en) 2011-06-25 2016-08-03 Xuanzhu Pharma Co., Ltd. C-glycoside derivatives
WO2013038429A2 (en) 2011-09-13 2013-03-21 Panacea Biotec Ltd. Novel sglt inhibitors
CN102408459B (zh) 2011-09-29 2014-07-23 天津药物研究院 一类含异头位烷基的苯基c-葡萄糖苷衍生物、其制备方法和用途
WO2013090550A1 (en) 2011-12-15 2013-06-20 National Health Research Institutes Novel glycoside compounds
WO2013178064A1 (zh) 2012-05-29 2013-12-05 广东东阳光药业有限公司 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
CN103570657A (zh) 2012-07-19 2014-02-12 天津药物研究院 一类含偕二甲基的苯基c-葡萄糖苷衍生物、其制备方法和用途
CN103772449B (zh) 2012-10-26 2017-12-26 上海阳帆医药科技有限公司 C‑芳基葡萄糖苷衍生物及其制备方法与用途
WO2014094544A1 (zh) 2012-12-17 2014-06-26 天津药物研究院 含脱氧葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途
WO2014164286A1 (en) 2013-03-11 2014-10-09 Janssen Pharmaceutica Nv Dual sglt1/sglt2 inhibitors
CN104059042B (zh) 2013-03-22 2017-02-08 正大天晴药业集团股份有限公司 C-三芳基葡萄糖苷类sglt-2抑制剂
WO2014187365A1 (zh) 2013-05-24 2014-11-27 四川海思科制药有限公司 氧杂双环衍生物、制备方法及其应用
WO2014206349A1 (zh) 2013-06-28 2014-12-31 四川海思科制药有限公司 氧杂-硫杂-双环[3.2.1]辛烷衍生物、制备方法及其用途
WO2015027963A1 (zh) 2013-09-02 2015-03-05 四川海思科制药有限公司 芳环类衍生物、其药物组合物及其应用
AU2014317663B2 (en) 2013-09-09 2018-02-08 Youngene Therapeutics Co., Ltd. C-aryl glucoside derivative, preparation method for same, and medical applications thereof
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1950389A (zh) * 2004-03-04 2007-04-18 橘生药品工业株式会社 含氮稠环衍生物，含该衍生物的药物组合物，和其作为药物的用途
CN1930141A (zh) * 2004-03-16 2007-03-14 贝林格尔·英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
CN102149717A (zh) * 2008-08-28 2011-08-10 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2,3,4-三醇衍生物
CN102372722A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors.;Vincent Mascitti, et al.,;《Journal of Medicinal Chemistry》;20110330;第54卷;第2952-2960页. *

Also Published As

Publication number Publication date
CA2889699A1 (en) 2015-04-02
WO2015043511A1 (en) 2015-04-02
CN104513283A (zh) 2015-04-15
HK1207075A1 (en) 2016-01-22
EP2895490A1 (en) 2015-07-22
EP2895490A4 (en) 2015-10-28
AU2014327928A1 (en) 2015-05-14
US20150266916A1 (en) 2015-09-24
JP6450769B2 (ja) 2019-01-09
JP2016535074A (ja) 2016-11-10
US9394329B2 (en) 2016-07-19
EP2895490B1 (en) 2016-10-19
ES2605886T3 (es) 2017-03-16
CA2889699C (en) 2017-06-06

Similar Documents

Publication Publication Date Title
CN104513283A (zh) 吡喃葡萄糖基衍生物及其在医药上的应用
CN110066302B (zh) 吡喃葡萄糖基衍生物及其用途
CN106083943B (zh) 一种吡喃葡萄糖基衍生物及其制备方法和用途
CN106892948B (zh) 吡喃葡萄糖基衍生物及其在医药上的应用
CN105461762A (zh) 吡喃葡萄糖基衍生物及其在医药上的应用
JP6373352B2 (ja) 細菌感染を処置するためのマンノース誘導体
CN103508931B (zh) 六氢并环戊二烯衍生物、其制备方法及其在医药上的应用
CN104447893B (zh) 吡喃葡萄糖基衍生物及其在医药上的应用
CN111630058B (zh) 吡喃葡萄糖基衍生物及其用途
US8921412B2 (en) C-aryl ansa SGLT2 inhibitors
AU2014327928B2 (en) Glucopyranosyl derivatives and their uses in medicine
CN108203432B (zh) 吡喃葡萄糖基衍生物及其在医药上的应用
CN106674245B (zh) 吡喃葡萄糖基衍生物的制备及医药上的应用
CN103450214B (zh) 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
CN103848806B (zh) 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
HK1207075B (en) Glucopyranosyl derivatives and their uses in medicine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180613

Address after: 523808 Songshan Lake Science and Technology Industrial Park, Dongguan, Guangdong (No. 1 Industrial North Road, Hubei Industrial Park, Songshan)

Co-patentee after: Ruyuan Yongxing Technical Service Co., Ltd.

Patentee after: Dongyangguang Pharmaceutical Co., Ltd., Guangdong

Address before: 523000 Songshan Lake Science and Technology Industrial Park, Dongguan, Guangdong (No. 1 Industrial North Road, Hubei Industrial Park, Songshan)

Patentee before: Dongyangguang Pharmaceutical Co., Ltd., Guangdong

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190905

Address after: 523808 Guangdong city of Dongguan province Hubei Songshan Industrial Park Industrial Road No. 1

Patentee after: Dongyangguang Pharmaceutical Co., Ltd., Guangdong

Address before: 523808 Songshan Lake Science and Technology Industrial Park, Dongguan City, Guangdong Province (No. 1 Industrial North Road, Songshan Hubei Industrial Park)

Co-patentee before: Ruyuan Yongxing Technical Service Co., Ltd.

Patentee before: Dongyangguang Pharmaceutical Co., Ltd., Guangdong

TR01 Transfer of patent right
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20150415

Assignee: YICHANG HEC CHANGJIANG PHARMACEUTICAL Co.,Ltd.

Assignor: SUNSHINE LAKE PHARMA Co.,Ltd.

Contract record no.: X2020980002998

Denomination of invention: Glucopyranose-based derivative and application of glucopyranose-based derivative in medicines

Granted publication date: 20180116

License type: Exclusive License

Record date: 20200611

EE01 Entry into force of recordation of patent licensing contract
EC01 Cancellation of recordation of patent licensing contract

Assignee: YICHANG HEC CHANGJIANG PHARMACEUTICAL Co.,Ltd.

Assignor: SUNSHINE LAKE PHARMA Co.,Ltd.

Contract record no.: X2020980002998

Date of cancellation: 20200824

EC01 Cancellation of recordation of patent licensing contract
TR01 Transfer of patent right

Effective date of registration: 20200909

Address after: 443300, No. 38, Binjiang Road, Yidu, Hubei, Yichang

Patentee after: YICHANG HEC CHANGJIANG PHARMACEUTICAL Co.,Ltd.

Address before: 523808 Guangdong city of Dongguan province Hubei Songshan Industrial Park Industrial Road No. 1

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.

TR01 Transfer of patent right